Oncology

Patients receiving chemotherapy
#Chemotherapy #Neuropathy #Oncology

Nerve health formulation launches in US to support chemotherapy patients

Novilora has launched in the US, bringing a science-based approach to supporting nerve health for people living through and beyond cancer treatment.   Formulated by Italian internist and oncologist Dr Raffaele Migliaccio and sold in Europe as OnLife, Novilora combines palmitoylethanolamide (PEA) with a defined profile of fatty… Read More

#News

Cancer cells
#Combination therapy #Faeth Therapeutics #Oncology #Phase II trial

Preliminary data indicate durable responses for combo cancer therapy 

Faeth Therapeutics has announced topline clinical data from its Phase II trial of PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib, given with paclitaxel.  The drug is being trialled in patients with advanced endometrioid endometrial cancer and a PI3K/AKT/mTOR (PAM) pathway mutation, who had received at… Read More

#Cancer Research #Editor's Choice #News

#Epitopea #Immunotherapy #mRNA #Oncology #Ovarian cancer #Phase I trial

First patient receives mRNA immunotherapy for ovarian cancer

The first patient has been successfully dosed in OVACT, Epitopea’s first-in-human Phase I/Ib clinical trial evaluating its lead programme, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer (HGSOC).  OVACT is designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in HRP+/BRCA-wildtype advanced HGSOC patients. … Read More

#Cancer Research #News #Trending News

Business deal agreement
#Antibody drug conjugate (ADC) #Boehringer Ingelheim #China #Collaboration #Oncology

Boehringer Ingelheim puts China strategy into action with SBP deal

Boehringer Ingelheim and China’s SBP Group have entered a strategic multi-programme agreement with to advance potential cancer treatments based on antibody-drug conjugate (ADC) and T-cell engager (TcE) technologies.   Building on the companies’ existing collaboration in oncology, the agreement will bring together SBP Group’s platforms and early-development capabilities… Read More

#Business & Investment #News

#mRNA #Oncology #Phase I trial #Strand Therapeutics

First patients receive mRNA therapy for tumour-selective activation

Strand Therapeutics has dosed the first patients in its ASCENT-1 Phase I clinical trial of STX-003, an intravenously delivered self-replicating mRNA therapy designed to selectively express IL-12 within tumours while restricting expression in healthy tissue.   This is the first clinical evaluation of Strand’s SignalLock genetic circuitry, designed… Read More

#Cancer Research #News

Immunotherapy
#ESMO #Immunotherapy #Oncology #Ovarian cancer #Phase I trial #TILT Biotherapeutics

TILT reports encouraging data at ESMO

Biotechnology company TILT Biotherapeutics has presented encouraging results for its TILT-123 therapy at the European Society for Medical Oncology (ESMO) Congress 2026. The company reported on the Phase Ib portion of its PROTA study, which is evaluating TILT-123 (igrelimogene litadenorepvec) in combination with MSD’s anti-PD-1 therapy Keytruda… Read More

#Cancer Research #News

Gut microbiome
#ESMO #Gut microbiome #Microbiotica #Oncology #Phase I trial

Trial data presented at ESMO support cancer microbiome therapy

Microbiotica has presented clinical data with encouraging efficacy from its Phase Ib MELODY-1 trial of MB097, a precision microbiome therapeutic for patients with advanced melanoma.  The data were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026.  The MELODY-1 trial… Read More

#Cancer Research #Editor's Choice #News #Trending News

#Antibody drug conjugate (ADC) #Biotech #Investment #Oncology #Women in STEM

Women in biopharma: Valerie Vanhooren, Ona Therapeutics 

In this series, DDW speaks to women in leading positions across biopharma about the work they’re doing and their experiences within the industry. Here, we speak to Valerie Vanhooren, Co-Founder & CEO, at Ona Therapeutics, about approaches in oncology, the remaining potential in the ADC field, and… Read More

#Exclusive Content

Cancer cell
#Breast cancer #ESMO #NEC Bio #Oncology #Phase II trial

NEC presents Phase I/II results for individualised oral neoantigen therapy

NEC Bio has presented results from the Phase I/II TNBC clinical trial of its orally administered individualised neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC).   The findings were presented in an e-poster at the ESMO Congress… Read More

#Cancer Research #News #Trending News

Monoclonal antibodies
#Colorectal cancer #GSK #Immunotherapy #Monoclonal antibodies #Oncology #US Food and Drug Administration (FDA)

FDA approves first immunotherapy for advanced rectal cancer

The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly).  The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer.  Patients with locally advanced… Read More

#Cancer Research #News #Regulatory #Trending News

Cancer cell
#Breast cancer #Cancer drug targets #Oncology #The Institute of Cancer Research

Breast cancer study uncovers potential new drug target

Scientists have uncovered a previously unknown mechanism that helps breast cancer cells survive the intense stresses of being malignant, revealing a promising new target for future cancer therapies.  A new study has shown that breast cancer cells become highly dependent on a cell membrane protein called GPR89… Read More

#Cancer Research #Editor's Choice #News

CAR-T in multiple myeloma
#CAR-T #Caribou Biosciences #Cell therapy #Haematology #Oncology

Caribou Biosciences cancels allogeneic CAR-T programmes

Caribou Biosciences has announced that it is discontinuing its two allogeneic CAR-T cell therapy programmes due to financing constraints.  It will discontinue development of vispa-cel for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for the treatment of r/r multiple myeloma. … Read More

#Cancer Research #News

MRI of the brain showing glioblastoma
#Brain cancer #Cancer vaccine #MimiVax #Oncology #Phase II trial

Cancer vaccine extends survival in glioblastoma trial

MimiVax and Roswell Park Comprehensive Cancer Center have announced results from the SURVIVE Phase IIb clinical trial evaluating novel cancer vaccine, SurVaxM, in patients with newly diagnosed glioblastoma.  The data reflect the first reportable results from the fully enrolled clinical trial, which has been underway since 2022… Read More

#Cancer Research #News